HRP20201263T1 - Natrijeva sol od n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida - Google Patents
Natrijeva sol od n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida Download PDFInfo
- Publication number
- HRP20201263T1 HRP20201263T1 HRP20201263TT HRP20201263T HRP20201263T1 HR P20201263 T1 HRP20201263 T1 HR P20201263T1 HR P20201263T T HRP20201263T T HR P20201263TT HR P20201263 T HRP20201263 T HR P20201263T HR P20201263 T1 HRP20201263 T1 HR P20201263T1
- Authority
- HR
- Croatia
- Prior art keywords
- salt
- indacen
- hexahydro
- pyrazole
- carbamoyl
- Prior art date
Links
- MTOUOUSKXWSTAX-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-(1-propan-2-ylpyrazol-3-yl)sulfonylurea Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)NS(=O)(=O)C1=NN(C=C1)C(C)C MTOUOUSKXWSTAX-UHFFFAOYSA-N 0.000 title claims 7
- 159000000000 sodium salts Chemical class 0.000 title claims 5
- 150000003839 salts Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 7
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 239000003960 organic solvent Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- CFFDCUJIVPXHRX-UHFFFAOYSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-(1-propan-2-ylpyrazol-3-yl)sulfonylurea hydrate Chemical compound O.C1CCC2=C(C=3CCCC3C=C12)NC(=O)NS(=O)(=O)C1=NN(C=C1)C(C)C CFFDCUJIVPXHRX-UHFFFAOYSA-N 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 201000002795 Muckle-Wells syndrome Diseases 0.000 claims 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000012296 anti-solvent Substances 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 2
- 206010072221 mevalonate kinase deficiency Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000002798 polar solvent Substances 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229910001415 sodium ion Inorganic materials 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000001839 Antisynthetase syndrome Diseases 0.000 claims 1
- 206010053555 Arthritis bacterial Diseases 0.000 claims 1
- 208000022715 Autoinflammatory syndrome Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 201000003274 CINCA syndrome Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010064568 Chronic infantile neurological cutaneous and articular syndrome Diseases 0.000 claims 1
- 241001475178 Dira Species 0.000 claims 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 claims 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010065159 Polychondritis Diseases 0.000 claims 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 208000010265 Sweet syndrome Diseases 0.000 claims 1
- ODDQLDNCAISQHR-UHFFFAOYSA-N [Na].C1CCC2=C(C=3CCCC3C=C12)NC(=O)NS(=O)(=O)C1=NN(C=C1)C(C)C Chemical compound [Na].C1CCC2=C(C=3CCCC3C=C12)NC(=O)NS(=O)(=O)C1=NN(C=C1)C(C)C ODDQLDNCAISQHR-UHFFFAOYSA-N 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000003608 autoimmunological effect Effects 0.000 claims 1
- 201000003308 autosomal dominant familial periodic fever Diseases 0.000 claims 1
- 208000025255 bacterial arthritis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 150000004682 monohydrates Chemical group 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000009169 relapsing polychondritis Diseases 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 230000037432 silent mutation Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 1
- 208000026082 sterile multifocal osteomyelitis with periostitis and pustulosis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (17)
1. Natrijeva sol od N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-l-izopropil-lH-pirazol-3-sulfonamida ili njezin hidrat ili solvat.
2. Sol sukladno zahtjevu 1, naznačena time što sol je mononatrijeva sol.
3. Sol sukladno zahtjevu 1 ili 2, naznačena time što je sol monohidrat.
4. Sol sukladno bilo kojem od zahtjeva 1 do 3, naznačena time što je sol kristalna.
5. Sol sukladno bilo kojem od zahtjeva 1 do 4, naznačena time što je sol kristalna mononatrijeva sol N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1H-pirazol-3-sulfonamid monohidrat.
6. Polimorfni oblik soli sukladno zahtjevu 5, ima XRPD spektar koji sadrži vrhove na: 4.3 ° 2θ, 8.7 ° 2θ i 20.6 ° 2θ, svih +0.2 ° 2θ.
7. Polimorfni oblik soli sukladno zahtjevu 5 ili 6, ima XRPD spektar u kojem 10 najintenzivnijih vrhova uključuje 5 ili više vrhova koji imaju vrijednost 2θ odabranu između: 4.3 ° 2θ, 6.2 ° 2θ, 6.7 ° 2θ, 7.3 ° 2θ, 8.7 ° 2θ, 9.0 ° 2θ, 12.1 ° 2θ, 15.8 ° 2θ, 16.5 ° 2θ, 18.0 ° 2θ, 18.1 ° 2θ, 20.6 ° 2θ, 21.6 ° 2θ, i 24.5 ° 2θ, svih +0.2 ° 2θ.
8. Postupak dobivanja natrijeve soli N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il) karbamoil)-1-izopropil-1H-pirazol-3-sulfonamida, koji sadrži:
(a) kontaktiranje N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1H-pirazol-3-sulfonamida bez kiseline i izvora natrijevih iona u prisutnosti jednog ili više polarnih otapala da nastane mješavina; i
(b) dobivanje krute natrijeve soli od N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il) karbamoil)-1-izopropil-1H-pirazol-3-sulfonamida iz mješavine.
9. Proces sukladno zahtjevu 8, naznačen time što jedno ili više polarnih otapala korištenih u koraku (a) sadrže vodu i polarno aprotično organsko otapalo.
10. Proces za pripremu kristalne mononatrijeve soli N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1H-pirazol-3-sulfonamid monohidrata u polimorfni oblik sukladno zahtjevu 6 ili 7, sadrži:
(a) kontaktiranje N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1H-pirazol-3-sulfonamida bez kiseline i izvora natrijevih iona u prisutnosti vode i izborno polarno aprotično organsko otapalo da se dobije otopina; ili otapanje N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1H-pirazol-3-sulfonamid mononatrijeve soli u mješavini otapala koja sadrži vodu i, izborno polarno aprotično organsko otapalo da se dobije otopina; i
(b) dobivanje kristalne mononatrijeve soli od N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1H-pirazol-3-sulfonamid monohidrata u polimorfni oblik sukladno zahtjevu 6 ili 7 iz otopine.
11. Proces sukladno zahtjevu 9 ili 10, naznačen time što polarno aprotično organsko otapalo korišteno u koraku (a) je aceton.
12. Proces sukladno bilo kojem od zahtjeva 8 do 11, naznačen time što natrijeva sol od N-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1H-pirazol-3-sulfonamida je dobivena u koraku (b) dodavanjem protuotapala.
13. Proces sukladno zahtjevu 12, naznačen time što protuotapalo je tert-butil metil eter.
14. Farmaceutski pripravak sadrži sol sukladno bilo kojem od zahtjeva 1 do 5, ili polimorfni oblik sukladno zahtjevu 6 ili 7, i farmaceutski prihvatljiv ekscipijent.
15. Sol sukladno bilo kojem od zahtjeva 1 do 5, ili polimorfni oblik sukladno zahtjevu 6 ili 7, ili farmaceutski pripravak iz zahtjeva 14, za uporabu u medicini.
16. Sol sukladno bilo kojem od zahtjeva 1 do 5, ili polimorfni oblik sukladno zahtjevu 6 ili 7, ili farmaceutski pripravak sukladno zahtjevu 14, za uporabu u liječenju ili sprječavanju bolesti, poremećaja ili stanja, pri čemu je bolest, poremećaj ili stanje odabrano između:
(i) upale;
(ii) auto-imunološke bolesti;
(iii) raka;
(iv) infekcije;
(v) bolesti središnjeg živčanog sustava;
(vi) metaboličke bolesti;
(vii) kardiovaskularne bolesti;
(viii) respiratorne bolesti;
(ix) bolesti jetre;
(x) bubrežne bolesti;
(xi) očne bolesti;
(xii) kožne bolesti;
(xiii) stanje limfe;
(xiv) psihološkog poremećaja;
(xv) cijepljenja nasuprot bolesti domaćina;
(xvi) alodnije; i
(xvii) svake bolesti za koju je određeno da pojedinac ima zaraznu ili somatsku nečujnu mutaciju u NLRP3.
17. Sol sukladno bilo kojem od zahtjeva 1 do 5, ili polimorfni oblik sukladno zahtjevu 6 ili 7, ili farmaceutski pripravak sukladno zahtjevu 14, za uporabu u liječenju ili sprječavanju bolesti, poremećaja ili stanja, pri čemu je bolest, poremećaj ili stanje odabrano između:
(i) periodičkih sindroma povezanih sa kriopirinom (CAPS);
(ii) Muckle-Wells sindroma (MWS);
(iii) obiteljskog autoinflamatornog sindroma (FCAS);
(iv) višesistemske upalne bolesti neonatalnog nastanka (NOMID);
(v) obiteljske mediteranske groznice (FMF);
(vi) piogenog artritisa, pioderma gangrenosuma i sindroma akni (PAPA);
(vii) hiperimunoglobulinemije D i sindroma periodične groznice (HIDS);
(viii) faktor nekroze tumora (TNF) periodičkog sindroma povezanog s receptorima (TRAPS);
(ix) sistemskog juvenilnog idiopatskog artritisa;
(x) Stillove bolesti odrasle osobe (AOSD);
(xi) relapsirajućeg polikondritisa;
(xii) Schnitzlerovog sindroma;
(xiii) Sweetovog sindroma;
(xiv) Behcetove bolesti;
(xv) sindroma anti-sintetaze;
(xvi) nedostatka antagonista receptora interleukina 1 (DIRA); i
(xvii) haploinsuficijencije A20 (HA20).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1806578.9A GB201806578D0 (en) | 2018-04-23 | 2018-04-23 | Novel compound |
| PCT/EP2019/060311 WO2019206871A1 (en) | 2018-04-23 | 2019-04-23 | A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
| EP19721230.1A EP3606909B1 (en) | 2018-04-23 | 2019-04-23 | A sodium salt of n-((1,2,3,5,6,7-hexahydro-s-indacen-4 -yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201263T1 true HRP20201263T1 (hr) | 2021-02-05 |
Family
ID=62236309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201263TT HRP20201263T1 (hr) | 2018-04-23 | 2020-08-11 | Natrijeva sol od n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10973803B2 (hr) |
| EP (2) | EP3606909B1 (hr) |
| JP (1) | JP7382958B2 (hr) |
| KR (1) | KR20210005589A (hr) |
| CN (1) | CN112020495B (hr) |
| AR (1) | AR114827A1 (hr) |
| AU (1) | AU2019257973A1 (hr) |
| BR (1) | BR112020021650A2 (hr) |
| CA (1) | CA3097832A1 (hr) |
| CY (1) | CY1123260T1 (hr) |
| DK (1) | DK3606909T3 (hr) |
| ES (1) | ES2811228T3 (hr) |
| GB (1) | GB201806578D0 (hr) |
| HR (1) | HRP20201263T1 (hr) |
| HU (1) | HUE050369T2 (hr) |
| LT (1) | LT3606909T (hr) |
| MA (2) | MA51082A (hr) |
| MD (1) | MD3606909T2 (hr) |
| ME (1) | ME03822B (hr) |
| MX (1) | MX2020011196A (hr) |
| PL (1) | PL3606909T3 (hr) |
| PT (1) | PT3606909T (hr) |
| RS (1) | RS60646B1 (hr) |
| SI (1) | SI3606909T1 (hr) |
| TW (1) | TW201943704A (hr) |
| UY (1) | UY38186A (hr) |
| WO (1) | WO2019206871A1 (hr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190111068A (ko) | 2017-01-23 | 2019-10-01 | 제넨테크, 인크. | 인터류킨-1 활성의 저해제로서의 화학적 화합물 |
| US11840543B2 (en) | 2017-05-24 | 2023-12-12 | The University Of Queensland | Compounds and uses |
| WO2019008029A1 (en) | 2017-07-07 | 2019-01-10 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| MX2020001778A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida. |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| WO2019034692A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| US11518739B2 (en) | 2017-08-15 | 2022-12-06 | Inflazome Limited | Sulfonamide carboxamide compounds |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| SG11202003984UA (en) | 2017-11-09 | 2020-05-28 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759078A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| EP3823726A1 (en) | 2018-07-20 | 2021-05-26 | F. Hoffmann-La Roche SA | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| US20220409585A1 (en) * | 2019-11-07 | 2022-12-29 | Inflazome Limited | Treatment of autoinflammatory disorders |
| JP2023501319A (ja) * | 2019-11-07 | 2023-01-18 | インフレイゾーム リミテッド | 神経変性疾患の処置および予防 |
| GB201916237D0 (en) * | 2019-11-07 | 2019-12-25 | Inflazome Ltd | Novel treatment |
| WO2021089781A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment or prevention of psychiatric brain disorders using the nlrp3 inhibitor n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1 -isopropyl-1 h-pyrazole-3-sulfonamide |
| US20220409586A1 (en) | 2019-11-07 | 2022-12-29 | Inflazome Limited | Treatment and prevention of neuroinflammation or an inflammatory brain disorder |
| WO2021089776A1 (en) * | 2019-11-07 | 2021-05-14 | Inflazome Limited | Treatment and prevention of a traumatic brain disorder |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4802908A (en) * | 1987-01-22 | 1989-02-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2-(1H)-pyrazinones |
| CA2383026A1 (en) * | 1999-09-14 | 2001-03-22 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| CN104023729A (zh) * | 2011-09-02 | 2014-09-03 | 协和发酵麒麟株式会社 | 趋化因子受体活性调节剂 |
| JP6929792B2 (ja) | 2015-02-16 | 2021-09-01 | ザ ユニバーシティ オブ クィーンズランド | スルホニル尿素及び関連化合物並びにその使用 |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| KR20180133244A (ko) | 2016-02-16 | 2018-12-13 | 더 유니버서티 어브 퀸슬랜드 | 설포닐유레아 및 관련 화합물 및 이의 용도 |
| ES2940611T3 (es) | 2016-04-18 | 2023-05-09 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| WO2017184623A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3272739A1 (en) | 2016-07-20 | 2018-01-24 | NodThera Limited | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
-
2018
- 2018-04-23 GB GBGB1806578.9A patent/GB201806578D0/en not_active Ceased
-
2019
- 2019-04-23 WO PCT/EP2019/060311 patent/WO2019206871A1/en unknown
- 2019-04-23 ME MEP-2020-173A patent/ME03822B/me unknown
- 2019-04-23 TW TW108114167A patent/TW201943704A/zh unknown
- 2019-04-23 ES ES19721230T patent/ES2811228T3/es active Active
- 2019-04-23 EP EP19721230.1A patent/EP3606909B1/en active Active
- 2019-04-23 CA CA3097832A patent/CA3097832A1/en active Pending
- 2019-04-23 RS RS20200936A patent/RS60646B1/sr unknown
- 2019-04-23 MA MA051082A patent/MA51082A/fr unknown
- 2019-04-23 DK DK19721230.1T patent/DK3606909T3/da active
- 2019-04-23 CN CN201980026640.0A patent/CN112020495B/zh active Active
- 2019-04-23 MA MA48051A patent/MA48051B1/fr unknown
- 2019-04-23 LT LTEP19721230.1T patent/LT3606909T/lt unknown
- 2019-04-23 AR ARP190101056A patent/AR114827A1/es unknown
- 2019-04-23 UY UY0001038186A patent/UY38186A/es not_active Application Discontinuation
- 2019-04-23 JP JP2020557902A patent/JP7382958B2/ja active Active
- 2019-04-23 PT PT197212301T patent/PT3606909T/pt unknown
- 2019-04-23 MD MDE20200181T patent/MD3606909T2/ro unknown
- 2019-04-23 BR BR112020021650-0A patent/BR112020021650A2/pt not_active Application Discontinuation
- 2019-04-23 PL PL19721230T patent/PL3606909T3/pl unknown
- 2019-04-23 EP EP20176198.8A patent/EP3722281A1/en not_active Withdrawn
- 2019-04-23 HU HUE19721230A patent/HUE050369T2/hu unknown
- 2019-04-23 SI SI201930005T patent/SI3606909T1/sl unknown
- 2019-04-23 MX MX2020011196A patent/MX2020011196A/es unknown
- 2019-04-23 KR KR1020207030023A patent/KR20210005589A/ko not_active Application Discontinuation
- 2019-04-23 AU AU2019257973A patent/AU2019257973A1/en not_active Abandoned
-
2020
- 2020-04-16 US US16/850,978 patent/US10973803B2/en active Active
- 2020-08-11 HR HRP20201263TT patent/HRP20201263T1/hr unknown
- 2020-08-12 CY CY20201100756T patent/CY1123260T1/el unknown
-
2021
- 2021-03-09 US US17/196,956 patent/US20210315862A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019206871A1 (en) | 2019-10-31 |
| ES2811228T3 (es) | 2021-03-11 |
| HUE050369T2 (hu) | 2020-11-30 |
| EP3722281A1 (en) | 2020-10-14 |
| AU2019257973A1 (en) | 2020-11-19 |
| MD3606909T2 (ro) | 2020-08-31 |
| EP3606909A1 (en) | 2020-02-12 |
| CY1123260T1 (el) | 2021-12-31 |
| JP2021522195A (ja) | 2021-08-30 |
| PL3606909T3 (pl) | 2020-11-16 |
| CN112020495B (zh) | 2024-05-17 |
| SI3606909T1 (sl) | 2020-09-30 |
| LT3606909T (lt) | 2020-10-12 |
| UY38186A (es) | 2019-11-29 |
| AR114827A1 (es) | 2020-10-21 |
| US10973803B2 (en) | 2021-04-13 |
| TW201943704A (zh) | 2019-11-16 |
| EP3606909B1 (en) | 2020-05-27 |
| CA3097832A1 (en) | 2019-10-31 |
| MX2020011196A (es) | 2020-11-13 |
| GB201806578D0 (en) | 2018-06-06 |
| ME03822B (me) | 2021-04-20 |
| RS60646B1 (sr) | 2020-09-30 |
| MA48051B1 (fr) | 2020-08-31 |
| PT3606909T (pt) | 2020-07-09 |
| DK3606909T3 (da) | 2020-08-24 |
| US20210315862A1 (en) | 2021-10-14 |
| US20200237723A1 (en) | 2020-07-30 |
| JP7382958B2 (ja) | 2023-11-17 |
| MA51082A (fr) | 2021-05-19 |
| KR20210005589A (ko) | 2021-01-14 |
| CN112020495A (zh) | 2020-12-01 |
| BR112020021650A2 (pt) | 2021-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201263T1 (hr) | Natrijeva sol od n-((1,2,3,5,6,7-heksahidro-s-indacen-4-il)karbamoil)-1-izopropil-1h-pirazol-3-sulfonamida | |
| RU2020110394A (ru) | Новые соединения сульфонамидкарбоксамидов | |
| RU2020110366A (ru) | Новые соединения сульфонамидкарбоксамидов | |
| RU2020115098A (ru) | Соединения новых сульфонамидкарбоксамидов | |
| JP7524172B2 (ja) | 新規な工程 | |
| IL271716B1 (en) | Sulfonamide Carboxamide Compounds as NLRP3 Inhibitors, Pharmaceutical Preparations and Their Uses | |
| ES2670571T3 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B | |
| ES2295031T3 (es) | Nuevos moduladores de interleucina-1 y factor de necrosis tumoral, sintesis de dichos moduladores y metodos de uso de dichos moduladores. | |
| US20210332020A1 (en) | Phenylsulfonylurea derivatives useful as nlrp3 inhibitors | |
| WO2020227549A8 (en) | MODULATORS OF THR-β AND METHODS OF USE THEREOF | |
| RU2018145808A (ru) | Производное фенилпропанамида, способ его получения и его фармацевтическое применение | |
| RU2308454C9 (ru) | Соединения, композиции на их основе и способы их использования | |
| HRP20200408T1 (hr) | Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa | |
| HRP20211782T1 (hr) | Derivati indola kao inhibitori replikacije denga virusa | |
| CA2749960A1 (en) | Agonists and antagonists of the s1p5 receptor, and methods of uses thereof | |
| TW200838497A (en) | Sphingosine-1-phosphate receptor agonist and antagonist compounds | |
| CA3078391A1 (en) | Cap-dependent endonuclease inhibitors | |
| CN115160297B (zh) | 杂芳基化合物及其制备方法和用途 | |
| JP6334066B2 (ja) | ヤヌスキナーゼ阻害剤としての置換されたＮ−（ピロリジン−３−イル）−７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−アミン | |
| JP2000505450A (ja) | キノロン類およびこれらの治療的使用 | |
| HRP20240896T1 (hr) | Derivati sulfoniluree i njihova upotreba | |
| Gao et al. | Interleukin-17: A putative novel pharmacological target for pathological pain | |
| WO2023220715A1 (en) | Oxoindolinyl amide derivatives for inhibiting nlrp3 and uses thereof | |
| RU2021106340A (ru) | Новые соединения сульфонамидов мочевины | |
| AU2019302611B2 (en) | Composition of Fused Tricyclic gamma-Amino Acid Derivatives and the Preparation Thereof |